Pacira BioSciences
PCRX
192 hedge funds and large institutions have $1.87B invested in Pacira BioSciences in 2017 Q1 according to their latest regulatory filings, with 54 funds opening new positions, 60 increasing their positions, 61 reducing their positions, and 36 closing their positions.
50% more first-time investments, than exits
New positions opened: 54 | Existing positions closed: 36
44% more capital invested
Capital invested by funds: $1.3B → $1.87B (+$571M)
35% more call options, than puts
Call options by funds: $26.8M | Put options by funds: $19.9M
5% more funds holding
Funds holding: 182 → 192 (+10)
1.85% more ownership
Funds ownership: 107.68% → 109.53% (+1.9%)
2% less repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 61
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$137M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
+$37.6M |
| 3 |
CCM
Cadian Capital Management
New York
|
+$26.6M |
| 4 |
Tudor Investment Corp
Stamford,
Connecticut
|
+$21.7M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$20.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$39.6M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$37.9M |
| 3 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$21.8M |
| 4 |
HM
HealthCor Management
New York
|
-$20.5M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$16.4M |
PCRX Hedge Fund Activity: Q1 2017 in Review
192 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q1 2017, worth a combined $1.87B — up 44% from $1.3B a quarter earlier.
Buyers outnumbered sellers: 54 funds opened new PCRX positions and 36 closed out — a net gain of 18 holders — while 60 added to existing stakes and 61 trimmed.
The largest buyer was BlackRock, adding an estimated $137M. The largest seller was Millennium Management, cutting an estimated $39.6M.
- 192 institutional investors held Pacira BioSciences (PCRX) as of Q1 2017, up from 182 in Q4 2016.
- Funds reported $1.87B of Pacira BioSciences stock for Q1 2017, up 44% quarter-over-quarter.
- 54 funds opened new Pacira BioSciences positions in Q1 2017 and 36 closed out, a net change of +18 holders.
- The largest Pacira BioSciences buyer in Q1 2017 was BlackRock, an estimated $137M added.
- The largest Pacira BioSciences seller in Q1 2017 was Millennium Management, an estimated $39.6M sold.
Based on aggregated 13F filings for Q1 2017.